- Home
- ORKT vs QTTB Comparison
ORKT vs QTTB Comparison
Compare ORKT & QTTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ORKT
- QTTB
- Stock Information
- Founded
- ORKT 2003
- QTTB 2015
- Country
- ORKT Singapore
- QTTB United States
- Employees
- ORKT N/A
- QTTB N/A
- Industry
- ORKT
- QTTB Biotechnology: Pharmaceutical Preparations
- Sector
- ORKT
- QTTB Health Care
- Exchange
- ORKT NYSE
- QTTB Nasdaq
- Market Cap
- ORKT 34.7M
- QTTB 40.0M
- IPO Year
- ORKT 2024
- QTTB N/A
- Fundamental
- Price
- ORKT $1.10
- QTTB $2.57
- Analyst Decision
- ORKT Strong Buy
- QTTB Hold
- Analyst Count
- ORKT 1
- QTTB 8
- Target Price
- ORKT $5.00
- QTTB $24.14
- AVG Volume (30 Days)
- ORKT 5.4M
- QTTB 253.9K
- Earning Date
- ORKT 10-16-2024
- QTTB 04-03-2025
- Dividend Yield
- ORKT N/A
- QTTB N/A
- EPS Growth
- ORKT N/A
- QTTB N/A
- EPS
- ORKT N/A
- QTTB N/A
- Revenue
- ORKT $3,904,592.00
- QTTB N/A
- Revenue This Year
- ORKT N/A
- QTTB N/A
- Revenue Next Year
- ORKT N/A
- QTTB N/A
- P/E Ratio
- ORKT N/A
- QTTB N/A
- Revenue Growth
- ORKT N/A
- QTTB N/A
- 52 Week Low
- ORKT $0.62
- QTTB $2.35
- 52 Week High
- ORKT $8.00
- QTTB $53.79
- Technical
- Relative Strength Index (RSI)
- ORKT N/A
- QTTB 27.14
- Support Level
- ORKT N/A
- QTTB $2.35
- Resistance Level
- ORKT N/A
- QTTB $2.75
- Average True Range (ATR)
- ORKT 0.00
- QTTB 0.22
- MACD
- ORKT 0.00
- QTTB 0.25
- Stochastic Oscillator
- ORKT 0.00
- QTTB 19.82
About ORKT ORANGEKLOUD TECHNOLOGY INC
Orangekloud Technology Inc is a company that operates through its subsidiaries provide IT consultancy services and distribution of related products and services. The Company also offers ERPs predominately in Singapore. It derives revenue from platform subscriptions, license and products and professional services.
About QTTB Q32 Bio Inc. Common Stock
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body's first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function. ADX-097, the lead product candidate from Q32's complement inhibitor platform, is a humanized anti-C3d monoclonal antibody fusion protein.